Butzner M, Maron M, Sarocco P, et al. - In the United States, the number of patients with clinically diagnosed hypertrophic cardiomyopathy (HC) rose 1.5-fold to ∼262,591 over 6 years (2013–2019), mainly due to an increase in nonobstructive HC diagnoses.

• Patients with ≥1 claim of HC International Classification of Diseases, Clinical Modification Ninth and Tenth Revision diagnosis codes were included (for years 2013–2019) from HealthCore Integrated Research Database.

• In 2013, 8526 of 16,243,109 patients had HC; estimated prevalence of clinically diagnosed HC was 0.052% (0.035% for obstructive [oHC], 0.017% for nonobstructive [nHC]).

• Incidence of new HC diagnoses, for the same year, was 0.030% (0.020% for oHC, 0.010% for nHC).

• Over the following 6 years, an increase in the prevalence and incidence of HC occurred by 0.005%/year and 0.001%/year, respectively, with an estimated 262,591 patients with a clinical diagnosis of HC in 2019.

• Over this period, an increase in nHC incidence whereas a decline in oHC incidence was observed.